Literature DB >> 22310608

Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation: a preliminary report.

T Zhao1, C Yang, Y Xue, Y Y Qiu, L Hu, Y Qiu, X Wang, B Yang, R Rong, M Xu, T Zhu.   

Abstract

OBJECT: This study aims to investigate the impact of anti-CD25 monoclonal antibody (basiliximab) on peripheral blood regulatory T cells (Treg) and their subsets in recipients early after renal transplantation.
METHODS: Ten renal transplant recipients from November 2009 to February 2011 were divided into an induction therapy and a no-induction therapy group, mainly based on their will to accept basiliximab induction. Peripheral blood samples were collected at 2 hours before as well as 1 and 2 weeks after transplantation. Flow cytometry was used to analyze the proportion of regulatory T cells and their subsets.
RESULTS: Compared with the no-induction therapy group, the proportions of both CD25(high) T cell and CD25(high) Foxp3(+) double marked T cells were significantly decreased among in the basiliximab induction group remaining at low at 2 weeks. The subsets of activated Treg and cytokine-secreting Treg were also temporarily downregulated at 1 week after transplantation using basiliximab induction. However, the inhibitory transcriptional factor Foxp3 was not significantly affected by the induction therapy.
CONCLUSIONS: Anti-CD25 monoclonal antibody downregulated the proportion of regulatory T cell and its activated subsets in peripheral blood in the early stage after renal transplantation while the inhibitory function may still be spared.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310608     DOI: 10.1016/j.transproceed.2011.11.026

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

Review 1.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

Review 2.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 3.  Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis.

Authors:  Kun Wang; Xianlin Xu; Min Fan
Journal:  Clin Exp Nephrol       Date:  2017-10-06       Impact factor: 2.801

4.  Pretransplant Levels of C-Reactive Protein, Soluble TNF Receptor-1, and CD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients.

Authors:  Jose F Camargo; Suresh Pallikkuth; Ilona Moroz; Yoichiro Natori; Maria L Alcaide; Allan Rodriguez; Giselle Guerra; George W Burke; Savita Pahwa
Journal:  Kidney Int Rep       Date:  2019-08-19

5.  Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD.

Authors:  Sybille Landwehr-Kenzel; Anne Zobel; Isabela Schmitt-Knosalla; Anne Forke; Henrike Hoffmann; Michael Schmueck-Henneresse; Robert Klopfleisch; Hans-Dieter Volk; Petra Reinke
Journal:  Front Immunol       Date:  2021-10-11       Impact factor: 7.561

6.  Generation and persistence of human tissue-resident memory T cells in lung transplantation.

Authors:  Mark E Snyder; Michael O Finlayson; Thomas J Connors; Pranay Dogra; Takashi Senda; Erin Bush; Dustin Carpenter; Charles Marboe; Luke Benvenuto; Lori Shah; Hilary Robbins; Jaime L Hook; Megan Sykes; Frank D'Ovidio; Matthew Bacchetta; Joshua R Sonett; David J Lederer; Selim Arcasoy; Peter A Sims; Donna L Farber
Journal:  Sci Immunol       Date:  2019-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.